References
- Hatch R, Rosenfield R L, Kim M H, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981; 140: 815–830
- Elsenbruch S, Hahn S, Kowalsky D. Quality of life, psychosocial well-being, and sexual satisfaction in women with polycistic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 5801–5807
- Hahn S, Janssen O E, Tan S, Pleger K, Mann K, Schedlowski M, Kimmig R, Benson S, Balamitsa E, Elsenbruch S. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Eur J Endocrinol 2005; 153: 853–860
- Lee A T, Zane L T. Dermatologic manifestations of polycystic ovary syndrome. Am J Clin Dermatol 2007; 8: 201–219
- Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R, Lanzone A. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004; 89: 2817–2823
- Muhn P, Fuhrmann U, Fritzemeier K H, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 1995; 761: 311–335
- Muhn P, Krattenmacher R, Beier S, Elger W, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception 1995; 51: 99–110
- van Vloten W A, van Haselen C W, van Zuuren E J, Gerlinger C, Heithecker R. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002; 69: 2–15
- Schramm G, Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolarebility and antiandrogenic properties. Contraception 2003; 67: 305–312
- Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs 2003; 63: 463–492
- Zahradnik H P. Belara – a reliable oral contraceptive with additional benefits for health and efficacy in dysmenorrhea. Eur J Contracept Reprod Health Care 2005; 1: 12–18
- Ferriman D, Gallwey J D. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21: 1440–1447
- Oelkers W H. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric 2005; 3: 19–27
- Rowlands S. Newer progestogens. J Fam Plann Reprod Health Care 2003; 29: 13–16
- Elger W, Beier S, Pollow K, Garfield R, Shi S Q, Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids 2003; 68: 891–905
- Batukan C, Muderris H, Ozcelik B, Ozturk B, Ozturk A. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecol Endocrinol 2007; 23: 38–44
- Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005; 8(suppl 1)3–63
- Schneider H P. Androgens and antiandrogens. Ann NY Acad Sci 2003; 997: 292–306
- Grosman N, Hvidberg E, Schou J. The effect of oestrogenic treatment on the acid mucopolysaccaride pattern in skin of mice. Acta Pharmacol Toxicol 1971; 30: 458–464
- Uzuka M, Nakajima K, Ohta S, Mori Y. The mechanism of estrogen-induced increase in hyaluronic acid biosynthesis, with special reference to estrogen receptor in the mouse skin. Biochim Biophys Acta 1980; 627: 199–206
- Pierard-Franchimond C, Letane C, Goffin V, Pierard G E. Skin water-holding capacity and transdermal estrogen therapy for menopause: a pilot study. Maturitas 1995; 22: 151–154